PS治疗新生儿MAS和NRDS的疗效及安全性

Efficacy and Safety of PS in the Treatment of MAS and NRDS in Neonates

目的:探讨肺表面活性物质(PS)治疗新生儿胎粪吸入综合征(MAS)和新生儿呼吸窘迫综合征(NRDS)的疗效及安全性。方法:选取在医院2015年12月～2017年8月期间诊治的55例MAS新生儿作为MAS组、55例NRDS新生儿作为NRDS组,实施PS治疗。结果:(1)MAS组新生儿治愈率是98.18%,与NRDS组新生儿治愈率86.36%相比无统计学差异(P>0.05);(2)MAS组新生儿并发症发生率是9.09%,与NRDS组的7.27%相比无统计学差异(P>0.05);(3)MAS组、NRDS组新生儿的氧合指数均低于治疗前(P<0.05),但治疗前后的氧合指数组间对比无统计学差异(P>0.05)。结论:PS治疗新生儿MAS和NRDS的疗效突出,且安全性较高,有借鉴意义。

Objective:To investigate the efficacy and safety of pulmonary surface active substance(PS)in the treatment of neonatal foetal aspiration syndrome(MAS)and neonatal respiratory distress syndrome(NRDS).Methods:55 cases of MAS neonates diagnosed and treated in the hospital from December 2015 to August 2017 were selected as the MAS group and 55 cases of NRDS neonates as the NRDS group for PS treatment.Results:(1)The cure rate of the newborn was 98.18%,compared with 86.36%in the NRDS group with no statistically significant difference(P>0.05).(2)The incidence of neonatal complications in MAS group was 9.09%,compared with 7.27%in NRDS group with no statistically significant difference(P>0 0.05).(3)The oxygenation index of neonates in the MAS group and NRDS group was lower than before the treatment(P<0.05),but there was no statistical difference between the oxygenation groups before and after treatment(P>0.05).Conclusion:PS therapy is effective in treating newborn MAS and NRDS,and is of high safety and significance.